Drugs in the US are expensive. The best in market Keytruda is even more expensive than blinutamab. The Oncarlytics trial is using blinutamab combined with CF33. Azercell can do the same job as blinutamab, if not better, we will see, and cheaper and more convenient. If the Oncarlytics trial goes well, then Imugene will test an Oncarlytics combination of Azercell with CF33. This is where game-changing potential is.
IMU Price at posting:
1.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)